Rodrigo Iñiguez García

Dr. Rodrigo Iñiguez García

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
Joaquin Martinez-LopezJoaquin Martinez-Lopez
Joaquin Martinez-Lopez
GHG. Hernandez-Ibarburu
G. Hernandez-Ibarburu
RAR. Alonso
R. Alonso
JSJ. M. Sanchez-Pina
J. M. Sanchez-Pina
IZI. Zamanillo
I. Zamanillo
JCJ. de la Cruz
J. de la Cruz
The COVID-19 pandemic has represented a major cause of morbidity/mortality worldwide, overstressing health systems. Multiple myeloma (MM) patients show an increased risk for infections and they are expected to be particularly vulnerable to SARS-CoV-2 infection. Here we have obtained a comprehensive picture of the impact of COVID-19 in MM patients on a local and a global scale using a federated data research network (TriNetX) that provided access to Electronic Medical Records (EMR) from Health Care Organizations (HCO) all over the world. Through propensity score matched analyses we found that the number of new diagnoses of MM was reduced in 2020 compared to 2019 (RR 0.86, 95%CI 0.76–0.96) and the survival of newly diagnosed MM cases decreased similarly (HR 0.61, 0.38–0.81). MM patients showed higher risk of SARS-CoV-2 infection (RR 2.09, 1.58–2.76) and a higher excess mortality in 2020 (difference in excess mortality 9%, 4.4–13.2) than non-MM patients. By interrogating large EMR datasets from HCO in Europe and globally, we confirmed that MM patients have been more severely impacted by COVID-19 pandemic than non-MM patients. This study highlights the necessity of extending preventive measures worlwide to protect vulnerable patients from SARS-CoV-2 infection by promoting social distancing and an intensive vaccination strategies.

1 November 2008 in Transplantation Proceedings
Verified
Journal Article
Closed access
VPV. Pinto
V. Pinto
JGJ. Grandy
J. Grandy
PZP. Zambrano
P. Zambrano
BCB. Corta
B. Corta
PSP. Salas
P. Salas
RGRodrigo Iñiguez García
Rodrigo Iñiguez García

28 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
RPRosa Pello
Rosa Pello
MPMaria de los Angeles Iglesias de la Puente
Maria de los Angeles Iglesias de la Puente
RVRaul Vidal
Raul Vidal
RMRaúl Mateos
Raúl Mateos
MPMarta Outón Porras
Marta Outón Porras
MCM TERESA CEDENA
M TERESA CEDENA
Background/Objectives: Therapeutic monoclonal antibodies, including bispecifics (t-mAbs), can interfere with serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE), mimicking residual M-protein. We evaluated a mass spectrometry (MS; EXENT®)-based workflow supported by an m/z reference library to discriminate drug from disease and assess concordance with IFE. Methods: Fifty-eight serum samples from 29 multiple myeloma patients were analyzed at baseline and after 3 months. Targeted enrichment of t-mAbs followed by MS enabled detection of peaks annotated through matching to a theoretical m/z panel and correlation with SPEP/IFE results. Results: Comparison of IFE versus MS showed 11/29 (38%) double positives, 15/29 (52%) double negatives, and 3/29 (10%) IFE−/MS+; no IFE+/MS− cases were observed. Using MS as a reference, IFE exhibited 78.6% sensitivity and 100% specificity. The m/z library enabled attribution of interference to linvoseltamab (n = 9), daratumumab (n = 6), and teclistamab (n = 3); in 16 patients treated with other bispecifics, no drug-related peaks were detected after 3 months. Longitudinal analysis discriminated therapeutic from endogenous immunoglobulins, identified baseline M-protein, and prevented false residual signals. Conclusions: MS (EXENT®)-based characterization of t-mAbs improves response monitoring accuracy in multiple myeloma and supports integration of MS into routine laboratory practice.

21 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MPMaria Poza
Maria Poza
AMAlejandro Martín-Muñoz
Alejandro Martín-Muñoz
PPPATRICIA LÓPEZ PEREIRA
PATRICIA LÓPEZ PEREIRA
GFGloria Figaredo
Gloria Figaredo
IZIrene Zamanillo
Irene Zamanillo
AUAna 1 Jiménez Ubieto
Ana 1 Jiménez Ubieto
Background/Objectives: This study aimed to determine whether interim PET/CT (iPET) scans could identify follicular lymphoma (FL) patients at high risk of relapse following first-line therapy. Methods: A total of 117 FL patients who underwent iPET scans were included, with responses interpreted using the Deauville score (DS). Progression-free survival (PFS) was evaluated over a median follow-up of 34 months. Results: Overall, 34% of patients were classified as iPET (+), with significantly worse estimated 5-year PFS compared to iPET (−) patients (34% vs. 76%, hazard ratio 4.3, p < 0.001). Multivariate analysis confirmed iPET (+) as an independent predictor of PFS. Conclusions: Interim PET results are significant predictors of PFS in FL first-line therapy and could inform response-adapted treatment strategies.

29 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MPMaria Poza
Maria Poza
AMAlejandro Martín-Muñoz
Alejandro Martín-Muñoz
PPPATRICIA LÓPEZ PEREIRA
PATRICIA LÓPEZ PEREIRA
GFGloria Figaredo
Gloria Figaredo
IZIrene Zamanillo
Irene Zamanillo
AUAna 1 Jiménez Ubieto
Ana 1 Jiménez Ubieto
Background/Objectives: This study aimed to determine whether interim PET/CT (iP-ET) scans could identify follicular lymphoma (FL) patients at high risk of relapse fol-lowing first-line therapy. Additionally, the potential of cell-free DNA (cfDNA) analysis to complement iPET in predicting outcomes was explored. Methods: A total of 121 FL patients who underwent iPET scans were included, with responses interpreted using the Deauville score (DS). Progression-free survival (PFS) was evaluated over a median follow-up of 34 months. Interim cfDNA data were analyzed for 14 patients to assess its potential for detecting false-positive PET results. Results: Overall, 34% of patients were classified as iPET(+), with significantly worse estimated 5-year PFS compared to iPET(-) patients (29% vs. 72%, hazard ratio 4.31, p < 0.001). Multivariate analysis confirmed iPET(+) as an independent predictor of PFS. Rituximab maintenance was predictive of reduced progression within the iPET(+) group but not among iPET(-) patients. cfDNA analysis identified two false-positive iPET cases and showed potential to identify pa-tients with complete response at risk of early progression. Conclusions: Interim PET results are significant predictors of PFS in FL first-line therapy and could inform re-sponse-adapted treatment strategies. cfDNA analysis has the potential to complement PET/CT by improving specificity and identifying patients at risk of early progression, offering a more precise approach to managing FL.